Showing 4021-4030 of 8129 results for "".
- Machine Learning Model Flags HS Up to Two Years Before Diagnosis: Reporthttps://practicaldermatology.com/news/machine-learning-model-flags-hidradenitis-suppurativa-up-to-two-years-before-diagnosis/2474208/A machine learning model analyzing U.S. insurance claims data was able to predict hidradenitis suppurativa (HS) up to two years before formal diagnosis, a new study shows. "Because the individual symptoms of cysts and abscesse
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo
- Review Unpacks Safety Data in Psoriasis Trialshttps://practicaldermatology.com/news/review-unpacks-safety-data-in-psoriasis-trials/2474174/While clinical trials frequently emphasize efficacy, safety data often remain inconsistently analyzed and underreported, according to the authors of a new review in the Journal of Clinical and Aesthetic Dermatology.
- CAB Gel Reduces Lesions and Preserves Skin Tone in Skin of Colorhttps://practicaldermatology.com/news/cab-gel-reduces-lesions-and-preserves-skin-tone-in-skin-of-color/2474010/A post hoc analysis of pooled Phase 2 and Phase 3 clinical trial data suggests that clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is effective and well tolerated for the treatment of moderate to severe acne in Black patients.
- Study: Dermabrasion Trials Rarely Report Race or Skin Typehttps://practicaldermatology.com/news/study-dermabrasion-trials-rarely-report-race-or-skin-type/2474005/Most clinical trials studying dermabrasion have failed to report racial or skin-type demographics, according to a new systematic review. "Clinical trials that are racially homogenous or do not report race limit the generalizab
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Obesity and Epidermal Innate Immunity Linked to Resistance to Biologic Therapy in Psoriasishttps://practicaldermatology.com/news/obesity-and-epidermal-innate-immunity-linked-to-resistance-to-biologic-therapy-in-psoriasis/2473927/Patients with severe plaque psoriasis who are overweight are more likely to experience resistance to biologic therapies, according to new findings The study researchers designed and conducted a cross-sectional study at Gachon
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- Report: Seborrheic Dermatitis Market Poised for Expansion through 2032https://practicaldermatology.com/news/report-seborrheic-dermatitis-market-poised-for-expansion-through-2032/2473856/The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight. The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) f